Author: Jane Edwards|| Date Published: January 9, 2023
An industry team consisting of Battelle, Andelyn Biosciences and AmplifyBio has secured a position on an eight-year, $149 million contract vehicle to provide support services for a National Institutes of Health research program focused on the development of treatments for neurological conditions.
The Central Ohio-based team will provide nonclinical and manufacturing support to help the National Institute of Neurological Disorders and Stroke advance the translational development of biological treatments under the multiple-award, indefinite-delivery/indefinite-quantity contract, Battelle said Friday.
“The contract will be used to advance innovative therapies, including cell and gene therapy, for a broad variety of neurological diseases,” said Drew Cawthon, business line director for Battelle’s life science research.
Jerry Hacker, executive vice president and chief commercial officer at AmplifyBio, said the company looks forward to contributing its preclinical study and therapy analytics capabilities to pursue the development of treatments for neurological conditions.
Battelle brings to the partnership its decades of experience in federal government contracting and assay and integration services to support regulatory approvals.
The Department of State has awarded spots on a multiple-award indefinite-delivery/indefinite-quantity contract with a combined potential value of $10 billion…
Brian Hobbs has been appointed CEO of Clarity Innovations, effective March 2, the company announced Tuesday. He succeeds founder and long-serving CEO Wes…
The Federal Aviation Administration has awarded a potential five-year, $437.4 million contract to ASRC Federal Advanced Research to provide second-level…
